XML 23 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2023
Apr. 22, 2024
Jun. 30, 2023
Document Information [Line Items]      
Entity, Registrant Name Anika Therapeutics, Inc.    
Current Fiscal Year End Date --12-31    
Document, Fiscal Period Focus FY    
Document, Fiscal Year Focus 2023    
Document, Type 10-K/A    
Document, Annual Report true    
Document, Period End Date Dec. 31, 2023    
Document, Transition Report false    
Entity, File Number 001-14027    
Entity, Incorporation, State or Country Code DE    
Entity, Tax Identification Number 04-3145961    
Entity, Address, Address Line One 32 Wiggins Avenue    
Entity, Address, City or Town Bedford    
Entity, Address, State or Province MA    
Entity, Address, Postal Zip Code 01730    
City Area Code 781    
Local Phone Number 457-9000    
Title of 12(b) Security Common Stock, par value $0.01 per share    
Trading Symbol ANIK    
Security Exchange Name NASDAQ    
Entity, Well-known Seasoned Issuer No    
Entity, Voluntary Filers No    
Entity, Current Reporting Status Yes    
Entity, Interactive Data, Current Yes    
Entity, Filer Category Accelerated Filer    
Entity, Small Business false    
Entity, Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document, Financial Statement Error Correction Flag false    
Entity, Shell Company false    
Entity, Public Float     $ 370,427,535
Entity, Common Stock Shares, Outstanding   14,828,456  
Amendment Description This Amendment No. 1 on Form 10-K/A, or the Amendment, amends the Annual Report on Form 10-K of Anika Therapeutics, Inc., a Delaware corporation, or we, our, us, Anika, or the Company, for the fiscal year ended December 31, 2023, originally filed with the Securities and Exchange Commission, or the SEC, on March 15, 2024, or the Original Filing. This Amendment is being filed to amend Part III of the Original Filing to include the information required by and not included in Part III of the Original Filing. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 4 and 5 of the certifications have been omitted. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.   Except for the matters described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing other than as expressly indicated in this Amendment. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company’s other filings made with the SEC on or subsequent to March 15, 2024.    
Amendment Flag true    
Entity, Central Index Key 0000898437